A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastat
A phase 2 trial of IBI363, Pembrolizumab in melanoma, run by Innovent Biologics (Suzhou) Co. Ltd., now recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy is a phase 2 interventional study registered as NCT06797297 by Innovent Biologics (Suzhou) Co. Ltd., with 180 participants planned, started 2025-02-24 and due to reach its primary completion in 2026-03-31. Interventions recorded: IBI363, Pembrolizumab. Conditions listed: Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of IBI363 in Subjects With Advanced Melanoma
Shares IBI363, Innovent Biologics, Melanoma.
- TrialA Study of IBI363 in Subjects with Advanced Solid Malignancies
Shares IBI363, Innovent Biologics, Melanoma.
- TrialIBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Shares IBI363, Innovent Biologics.
- TrialIBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small
Shares IBI363, Innovent Biologics, Pembrolizumab.